Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles

Open Access

Original Article

Desmoid tumour, a rare tumour in oncology practice: A case series and literature review

Erkan Erdur, Ferit Aslan.

Aim: Desmoid tumors (DTs) are very rare tumors that grow gradually anywhere in the body they are locally aggressive, but with a low potential for metastasis. Very good results can be obtained with different combinations of treatments, such as surgery, chemotherapy, hormonal therapy, tyrosine kinase inhibitor therapy and radiotherapy. Case series even with a small number of patients are of considerable importance as experience with DTs limited. Therefore, in this study, we aimed to discuss the management of DTs with our case series.
Materials and Methods: In our study, 15 patients with DT, who were treated and followed up between January 2005 and January 2020 in two hospital medical oncology departments in Turkey, were evaluated.
Results: The median age of diagnosis of the patients was 34 (range 18-48) years. Seven (46.6%) of the patients were female and eight (53.4%) were male. Seven (46.6%) of the tumors were located in the abdominal wall, four (26.7%) were in the limbs three (20%) were in the intra-abdominal area, and one (6.7%) was in the chest wall. In terms of resectability, 14 (93.3%) were resectable, and one (6.7%) was unresectable. The five-year overall survival rate was 73.85%, and the average disease-free survival time until relapse was 35 (range 15-83) months in patients who relapsed. The two- and five-year relapse-free survival rates were 90.9% and 66.5%, respectively. The median progression-free survival (PFS) for first-line treatment was 25 (range 8.6-89.8) months. The median PFS for second-line treatment was seven (range 4.3-38.0) months. In the one patient who received third-line treatment, PFS was 8.3 months.
Conclusion: Frequent relapses in DTs are still the biggest problem in treating this disease. Although surgery treatment is the main treatment method used in desmoid tumors, controversy about adjuvant therapy after surgery continues, and new treatment modalities are required.

Key words: Desmoid tumors; recurrence; sulindac; survival; tamoxifen

Similar Articles

New insights into Epstein‑Barr virus‑associated tumors: Exosomes (Review).
Chen W, Xie Y, Wang T, Wang L
Oncology reports. 2022; 47(1):

Neutrophil-to-lymphocyte ratio in sporadic amyotrophic lateral sclerosis.
Wei QQ, Hou YB, Zhang LY, Ou RW, Cao B, Chen YP, Shang HF
Neural regeneration research. 2022; 17(4): 875-880

Striatal oxidative damages and neuroinflammation correlate with progression and survival of Lewy body and Alzheimer diseases.
Li H, Knight WC, Xu J
Neural regeneration research. 2022; 17(4): 867-874

Radiofrequency thermocoagulation for the treatment of trigeminal neuralgia.
Wang Z, Wang Z, Li K, Su X, Du C, Tian Y
Experimental and therapeutic medicine. 2022; 23(1): 17

Long non-coding RNA H19 mediates N-acetyltransferase 1 gene methylation in the development of tamoxifen resistance in breast cancer.
Sun H, Wang G, Cai J, Wei X, Zeng Y, Peng Y, Zhuang J
Experimental and therapeutic medicine. 2022; 23(1): 12

Full-text options

Latest Statistics about COVID-19
• pubstat.org

Add your Article(s) to Indexes
• citeindex.org

Covid-19 Trends and Statistics
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.

ScopeMed Web Sites